Truist Financial Remains Bullish on Praxis Precision Medicines (PRAX)

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) is one of the 13 Small Cap Stocks Analysts Are Bullish On. On June 12, Truist Financial analyst Joon Lee maintained a Buy rating on Praxis Precision Medicines, Inc. (NASDAQ:PRAX) without a price target.

The company reported in its fiscal Q1 2025 results that it is on track for six major study readouts across four programs over 12 months, and is ready to start the pivotal studies in two developmental and epileptic encephalopathy (DEE) programs in mid-year 2025. These include the EMERALD for broad DEEs with relutrigine and EMBRAVE3 for SCN2A GoF with elsunersen.

A scientist wearing a lab coat, surrounded by vivid blue-themed biopharmaceutical equipment in a research laboratory.

Management anticipates topline near-term results for vormatrigine from the RADIANT study in epilepsy by mid-2025, along with the POWER1 study in H2 2025. Vormatrigine is continuing to exhibit competitive differentiation and an ideal profile, bringing a positive light to Praxis Precision Medicines, Inc. (NASDAQ:PRAX).

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) is a clinical-stage biopharmaceutical company that develops therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. The company focuses on two proprietary platforms: Cerebrum and Solidus.

While we acknowledge the potential of PRAX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.